BACKGROUND: Cyclo-oxygenase (COX) inhibition by indomethacin does not result in an improvement in long-term neurocognitive outcome, despite reducing the incidence of both severe intraventricular haemorrhage and white matter injury visible on ultrasound. Diffuse brain injury after preterm birth may have inflammatory origins. These two points suggest that, in the preterm brain, COX inhibition may have a dominant proinflammatory or neuropathological role. The inducible form of the COX2 gene is polymorphic: the -765 C (rather than G) variant of the gene is associated with reduced COX2 activity. OBJECTIVE: To test the hypothesis that the C allele of COX2 is associated with worse neurodevelopmental outcomes after premature birth. OUTCOMES: Cerebral palsy, disability, Griffith's developmental quotient at 2 years and British Ability Scales-11 general cognitive ability and motor performance (movement assessment battery for children) at 5(1/2) years were compared with COX2 genotype. RESULTS: The C allele (GC 65 (31%), CC 3 (1%)) was independently associated with worse cognitive performance at 2 and 5(1/2) years: C allele mean (SEM) developmental quotient 92.7 (1.7), v GG 97.6 (1.5), p = 0.039; C allele mean (SEM) general cognitive ability, 94.3 (2.2) v GG 100.9 (1.7), p = 0.028. CONCLUSION: An antineuropathological role for COX2 in the preterm brain may help account for the lack of effect of indomethacin treatment in improving neurocognitive outcomes in children born preterm, despite reported reduction in apparent brain injury.
BACKGROUND: Cyclo-oxygenase (COX) inhibition by indomethacin does not result in an improvement in long-term neurocognitive outcome, despite reducing the incidence of both severe intraventricular haemorrhage and white matter injury visible on ultrasound. Diffuse brain injury after preterm birth may have inflammatory origins. These two points suggest that, in the preterm brain, COX inhibition may have a dominant proinflammatory or neuropathological role. The inducible form of the COX2 gene is polymorphic: the -765 C (rather than G) variant of the gene is associated with reduced COX2 activity. OBJECTIVE: To test the hypothesis that the C allele of COX2 is associated with worse neurodevelopmental outcomes after premature birth. OUTCOMES: Cerebral palsy, disability, Griffith's developmental quotient at 2 years and British Ability Scales-11 general cognitive ability and motor performance (movement assessment battery for children) at 5(1/2) years were compared with COX2 genotype. RESULTS: The C allele (GC 65 (31%), CC 3 (1%)) was independently associated with worse cognitive performance at 2 and 5(1/2) years: C allele mean (SEM) developmental quotient 92.7 (1.7), v GG 97.6 (1.5), p = 0.039; C allele mean (SEM) general cognitive ability, 94.3 (2.2) v GG 100.9 (1.7), p = 0.028. CONCLUSION: An antineuropathological role for COX2 in the preterm brain may help account for the lack of effect of indomethacin treatment in improving neurocognitive outcomes in children born preterm, despite reported reduction in apparent brain injury.
Authors: Anastasia Papafili; Michael R Hill; David J Brull; Robin J McAnulty; Richard P Marshall; Steve E Humphries; Geoffrey J Laurent Journal: Arterioscler Thromb Vasc Biol Date: 2002-10-01 Impact factor: 8.311
Authors: Francesco Cipollone; Maria Fazia; Annalisa Iezzi; Giovanni Ciabattoni; Barbara Pini; Chiara Cuccurullo; Sante Ucchino; Francesco Spigonardo; Mariella De Luca; Cesaria Prontera; Francesco Chiarelli; Franco Cuccurullo; Andrea Mezzetti Journal: Arterioscler Thromb Vasc Biol Date: 2004-05-20 Impact factor: 8.311
Authors: A L Stewart; L Rifkin; P N Amess; V Kirkbride; J P Townsend; D H Miller; S W Lewis; D P Kingsley; I F Moseley; O Foster; R M Murray Journal: Lancet Date: 1999-05-15 Impact factor: 79.321
Authors: Augusto F Schmidt; Paranthaman S Kannan; Claire A Chougnet; Steve C Danzer; Lisa A Miller; Alan H Jobe; Suhas G Kallapur Journal: J Neuroinflammation Date: 2016-09-06 Impact factor: 8.322